Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer
Phase 3
Completed
- Conditions
- Breast Cancer FemaleHormone Receptor Positive Malignant Neoplasm of Breast
- Interventions
- Drug: Endocrine therapy
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2023-03-10
- Lead Sponsor
- Kyoto Breast Cancer Research Network
- Target Recruit Count
- 141
- Registration Number
- NCT03969121
- Locations
- π―π΅
Saitama Cancer Center, Saitama, Japan
π―π΅Toranomon Hospital, Tokyo, Japan
π―π΅Tokyo Metropolitan Komagome Hospital, Tokyo, Japan
Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer
Phase 2
Terminated
- Conditions
- Breast Cancer
- Interventions
- Drug: Durvalmab&Tremelimumab&Fulvestrant
- First Posted Date
- 2018-02-13
- Last Posted Date
- 2020-08-12
- Lead Sponsor
- Kyoto Breast Cancer Research Network
- Target Recruit Count
- 1
- Registration Number
- NCT03430466
- Locations
- π―π΅
Kyoto University Hospital, Kyoto, Japan
Anti PD-1 Antibody With Radiation Therapy in Patients With HER2-negative Metastatic Breast Cancer
Phase 1
Completed
- Conditions
- Breast Cancer
- Interventions
- Drug: Cohort A
- First Posted Date
- 2018-02-13
- Last Posted Date
- 2023-01-19
- Lead Sponsor
- Kyoto Breast Cancer Research Network
- Target Recruit Count
- 32
- Registration Number
- NCT03430479
- Locations
- π―π΅
Kyoto University Hospital, Kyoto, Japan
Β© Copyright 2025. All Rights Reserved by MedPath